Vironexis Trial Patients Achieved Complete Responses
Three leukemia patients reached MRD-negative status following a single administration of the gene therapy VNX-101.
Updated on Sept. 21, 2026 in Biotech
Live Poll
Should medical research prioritize one-time, durable treatments over traditional, repeated long-term therapies?
Three patients with relapsed or refractory acute lymphoblastic leukemia have achieved MRD-negative complete responses after receiving Vironexis’s experimental therapy, VNX-101. The treatment aims to serve as a one-time alternative to continuous protein infusions for blood cancer patients.
Why it matters
The trial results suggest that turning the liver into a biofactory for therapeutic proteins could provide a durable, single-dose solution for hematologic malignancies. This approach aims to eliminate the need for ongoing, repeated medical interventions.
VNX-101 is engineered to prompt the liver to produce CD19/CD3 protein in the body, with clinical responses confirmed via clonoSEQ and PET imaging. Nine total patients have been dosed across multiple hematologic malignancies in the SENTRY-CD19 study.
The players
Vironexis
This biotechnology firm is focused on developing one-time gene therapy solutions to treat blood-related cancers and hematologic malignancies.
Kevin Sharer
He was recently appointed as the Chairman of the Board of Directors for Vironexis to help guide the company's strategic development.
Dr. James Allison
A renowned immunologist who has joined the Scientific Advisory Board at Vironexis to support the advancement of their therapeutic pipeline.
The details
The treatment works by modifying the body to act as a biofactory for protein production, with clinical results showing successful responses in patients with extramedullary disease within 28 days. While side effects including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome were observed, investigators reported that these events have resolved.
Timeline
One patient achieved a complete response on PET imaging within 28 days.
The first patient remained MRD-negative through Day 260.
Vironexis released the trial results and board updates on Sept. 21, 2026.
Additional clinical study sites in South Korea are expected to activate in the coming weeks.
The Tech Race
This development marks a transition from standard infusion-based cancer treatments toward liver-targeted gene therapy biofactories. This positions Vironexis to compete against established cellular therapy providers by offering a potentially more durable, one-time treatment option.
The potential success of a one-time treatment could eventually replace the need for patients with blood cancer to undergo continuous, hospital-based protein infusions. This would significantly reduce the long-term clinical burden and treatment schedule for those managing refractory leukemia.
The takeaway
The study demonstrates that gene therapy can successfully turn the liver into an endogenous protein factory for sustained cancer treatment. This paradigm shift could redefine long-term care for refractory leukemia by prioritizing singular, durable interventions over chronic therapy cycles.
What happens next
Clinical sites in South Korea are scheduled to begin patient enrollment and study activities in the coming weeks.
Further reading
For more information on current treatment trials, explore the Biotech section.
More information
View the official clinical trial listing information to track updates on study progress.
Live Poll
Should medical research prioritize one-time, durable treatments over traditional, repeated long-term therapies?
